Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase - PubMed (original) (raw)
Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase
S Lindstedt et al. Lancet. 1992.
Abstract
Liver transplantation is the only effective treatment for hereditary tyrosinaemia type I (McKusick 276700). We have treated one acute and four subacute-chronic cases with 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC), a potent inhibitor of 4-hydroxyphenylpyruvate dioxygenase (EC 1.13.11.27), to prevent the formation of maleylacetoacetate and fumarylacetoacetate and their saturated derivatives. The oral daily dose was 0.1-0.6 mg/kg. The excretion of succinylacetoacetate and succinylacetone decreased from 15-103 mmol/mol creatinine to the detection limit or slightly above (ie, to 20-150 mumol/mol creatinine). The concentration of succinylacetone in plasma decreased from 5.8-43 mumol/l to the detection limit (0.1 mumol/l) over 2-5 months of treatment. The almost complete inhibition of porphobilinogen synthase in erythrocytes was abolished and the excretion of 5-aminolevulinate decreased to within or slightly above the reference range. The concentration of alpha-fetoprotein decreased in four patients to 1.3-7.5% of initially high values over 6-8 months. Improved liver function was reflected by normal concentrations of prothrombin complex and in decreased activities of alkaline phosphatase and gamma-glutamyltransferase in serum. Computed tomography revealed regression of hepatic abnormalities in three patients. One patient developed rickets 6 months before treatment and had excreted high concentrations of markers of tubular dysfunction--after 3 weeks of treatment, this excretion had disappeared. No side-effects were encountered. Inhibition of 4-hydroxyphenylpyruvate dioxygenase may prevent the development of liver cirrhosis and abolish or diminish the risk of liver cancer. Normalisation of porphyrin synthesis will eliminate the risk of porphyric crises. This type of treatment may thus offer an alternative to liver transplantation in hereditary tyrosinaemia.
Comment in
- New treatment for tyrosinaemia.
[No authors listed] [No authors listed] Lancet. 1992 Oct 3;340(8823):822-3. Lancet. 1992. PMID: 1357248 No abstract available.
Similar articles
- Tyrosinaemia type I and NTBC (2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione).
Holme E, Lindstedt S. Holme E, et al. J Inherit Metab Dis. 1998 Aug;21(5):507-17. doi: 10.1023/a:1005410820201. J Inherit Metab Dis. 1998. PMID: 9728331 Review. - Treatment of two children with hereditary tyrosinaemia type I and long-standing renal disease with a 4-hydroxyphenylpyruvate dioxygenase inhibitor (NTBC).
Pronicka E, Rowinska E, Bentkowski Z, Zawadzki J, Holme E, Lindstedt S. Pronicka E, et al. J Inherit Metab Dis. 1996;19(2):234-8. doi: 10.1007/BF01799438. J Inherit Metab Dis. 1996. PMID: 8739974 No abstract available. - [Favorable outcome of treatment with NTBC of acute liver insufficiency disclosing hereditary tyrosinemia type I].
Barkaoui E, Debray D, Habès D, Ogier H, Bernard O. Barkaoui E, et al. Arch Pediatr. 1999 May;6(5):540-4. doi: 10.1016/s0929-693x(99)80562-4. Arch Pediatr. 1999. PMID: 10370811 French. - New treatment for tyrosinaemia.
[No authors listed] [No authors listed] Lancet. 1992 Oct 3;340(8823):822-3. Lancet. 1992. PMID: 1357248 No abstract available. - From toxicological problem to therapeutic use: the discovery of the mode of action of 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC), its toxicology and development as a drug.
Lock EA, Ellis MK, Gaskin P, Robinson M, Auton TR, Provan WM, Smith LL, Prisbylla MP, Mutter LC, Lee DL. Lock EA, et al. J Inherit Metab Dis. 1998 Aug;21(5):498-506. doi: 10.1023/a:1005458703363. J Inherit Metab Dis. 1998. PMID: 9728330 Review.
Cited by
- Severe neurological crisis in adult patients with Tyrosinemia type 1.
Dawson C, Ramachandran R, Safdar S, Murphy E, Swayne O, Katz J, Newsome PN, Geberhiwot T. Dawson C, et al. Ann Clin Transl Neurol. 2020 Sep;7(9):1732-1737. doi: 10.1002/acn3.51160. Epub 2020 Aug 21. Ann Clin Transl Neurol. 2020. PMID: 32820610 Free PMC article. - Efficient liver repopulation of transplanted hepatocyte prevents cirrhosis in a rat model of hereditary tyrosinemia type I.
Zhang L, Shao Y, Li L, Tian F, Cen J, Chen X, Hu D, Zhou Y, Xie W, Zheng Y, Ji Y, Liu M, Li D, Hui L. Zhang L, et al. Sci Rep. 2016 Aug 11;6:31460. doi: 10.1038/srep31460. Sci Rep. 2016. PMID: 27510266 Free PMC article. - Transcriptome analysis of Paracoccidioides brasiliensis cells undergoing mycelium-to-yeast transition.
Nunes LR, Costa de Oliveira R, Leite DB, da Silva VS, dos Reis Marques E, da Silva Ferreira ME, Ribeiro DC, de Souza Bernardes LA, Goldman MH, Puccia R, Travassos LR, Batista WL, Nóbrega MP, Nobrega FG, Yang DY, de Bragança Pereira CA, Goldman GH. Nunes LR, et al. Eukaryot Cell. 2005 Dec;4(12):2115-28. doi: 10.1128/EC.4.12.2115-2128.2005. Eukaryot Cell. 2005. PMID: 16339729 Free PMC article. - Organ transplantation for inherited metabolic disease.
Kelly DA. Kelly DA. Arch Dis Child. 1994 Sep;71(3):181-3. doi: 10.1136/adc.71.3.181. Arch Dis Child. 1994. PMID: 7979487 Free PMC article. Review. - Physical Growth of Patients with Hereditary Tyrosinaemia Type I: A Single-Centre Retrospective Study.
Yilmaz O, Daly A, Pinto A, Ashmore C, Evans S, Gupte G, Jackson R, Yabanci Ayhan N, MacDonald A. Yilmaz O, et al. Nutrients. 2021 Aug 31;13(9):3070. doi: 10.3390/nu13093070. Nutrients. 2021. PMID: 34578949 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical